GlassScriptPhysician profile
Vinicius Ernani
NPI 1437460532
$37,488.12
in general payments reported to CMS, 2019-2025
13 companies · $6,798 in 2025
The $6,798 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $555 · 2021: $2,197 · 2022: $8,494 · 2024: $6,288 · 2025: $6,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $1,394 · Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,121.25 |
| Travel and Lodging | $1,393.67 |
| Food and Beverage | $571.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15,405.47 | 2019-2024 | |
| Janssen Biotech, INC. | $9,571.90 | 2024-2025 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $8,356.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $1,590.00 | 2022 | |
| Daiichi Sankyo INC. | $1,433.39 | 2022-2024 | |
| Astrazeneca Uk Limited | $539.83 | 2024 | |
| Tersera Therapeutics LLC | $237.16 | 2021 | |
| Aveo Pharmaceuticals, INC. | $160.60 | 2025 | |
| Ethicon US, LLC | $136.11 | 2024 | Neuwave |
| Pfizer INC. | $57.27 | 2021-2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinicius Ernani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.